Investor Type | Firm |
Type of Fund | Venture Capital Fund |
Industries | IT (& TMT) • BioTech • HealthTech (& Fitness) • Medical Devices (& Hospital Services) |
Stages | Early Stage, Expansion, Later Stage |
Investing | United States • India • China • Russia • Taiwan |
Investment Range | $1,000,000 - $16,500,000 |
Biomark Capital is a venture capital and private equity firm specializing in equity investments with a focus on life sciences and healthcare sectors. Established in 2013, Biomark Capital extends its financial acumen and operational expertise to early, mid, and later-stage companies innovating in therapeutics, medical devices, molecular diagnostics, and healthcare delivery and information technology. Operating with a deep commitment to fostering cutting-edge healthcare innovation, they target companies that develop novel approaches to diagnostics, therapeutics, medical devices, and digital health—a vision aimed at transforming the landscape of healthcare. Biomark Capital's investment strategy revolves around collaboration with their portfolio companies, contributing significantly not just with capital, but also by accelerating growth and building successful business ventures. This collaboration is part of their broader mission: to improve the human condition by creating value for the most promising life science companies. This mission is underpinned by their belief in the potential of their select investments to effect substantial improvements in healthcare outcomes. With a minimum investment of $1,000,000 and a maximum of $16,500,000, Biomark Capital offers financial support across the early stage, expansion, and later stage development phases. Headquartered at 537 Steamboat Road, Suite 200, Greenwich, Connecticut, they have additional offices in San Francisco, California, and Moscow, Russia, emphasizing their global reach and the cross-border nature of their investment approach.